A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
R-Pharm
Mayo Clinic
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Dana-Farber Cancer Institute
City of Hope Medical Center
Hospital of Stomatology, Wuhan University
GlaxoSmithKline
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
The University of Texas Health Science Center at San Antonio
AIO-Studien-gGmbH
Bristol-Myers Squibb
Groupe Oncologie Radiotherapie Tete et Cou
Arbeitsgemeinschaft medikamentoese Tumortherapie
Wake Forest University Health Sciences
Barbara Ann Karmanos Cancer Institute
Radiation Therapy Oncology Group
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Ohio State University Comprehensive Cancer Center
Seagen Inc.
Groupe Oncologie Radiotherapie Tete et Cou
Dana-Farber Cancer Institute
Massachusetts General Hospital
Dana-Farber Cancer Institute
Lithuanian University of Health Sciences
New Mexico Cancer Research Alliance
Case Comprehensive Cancer Center
University of Leipzig
National Cancer Institute (NCI)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
SWOG Cancer Research Network
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
SWOG Cancer Research Network
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute